ライフサイエンスコーパス: relative risk

1 identified only top 10% as having a similar relative risk.

2 sed random-effects models to estimate pooled relative risks.

3 ed large contemporary population rates using relative risks.

4 with 4-way decomposition to estimate excess relative risks.

5 postoperative IAA versus 16% in the NI arm (relative risk 0.72, 95% credible interval 0.38-1.23).

6 patients given placebo or active comparator (relative risk 0.72; 95% confidence interval 0.40-1.28).

7 risk of proximal colon cancer (multivariable relative risk 0.86; 95% CI 0.65-1.14; P-trend = .31).

8 cebo, a difference that was not significant: relative risk 0.90 (97.8% CI 0.72, 1.15; p=0.34).

9 f 612 infants in the control group (adjusted relative risk 0.95 [95% CI 0.78 to 1.16], p=0.61; adjust

10 reduced the risk of depression among women (relative risk = 0.44, 95% confidence interval: 0.24, 0.7

11 h a lower risk of developing this phenotype (relative risk = 0.76, 95% confidence interval: 0.59, 0.9

12 pared with eyes treated with >3 drops daily (relative risk, 0.13; 95% CI, 0.02-0.69; P = 0.02).

13 lower 90-day mortality than use of placebo (relative risk, 0.19; 95% CI, 0.05 to 0.75), whereas late

14 uL (9.2%) between months 18 and 30 (adjusted relative risk, 0.30 [95% confidence interval, .12-.74];

15 h-flow nasal cannula decreased reintubation (relative risk, 0.46; 95% CI, 0.30-0.70; moderate certain

16 nty) and postextubation respiratory failure (relative risk, 0.52; 95% CI, 0.30-0.91; very low certain

17 , -6.1 incident cases per 1000 person-years; relative risk, 0.55 [0.37-0.83]), or P2Y12 inhibitor mon

18 (difference, -10.0%; 95% CI, -18.3 to -1.6; relative risk, 0.556; 95% CI, 0.332 to 0.924; P = .02).

19 , -4.6 incident cases per 1000 person-years; relative risk, 0.61 [0.45-0.83]), and short-term DAPT fo

20 e difference, -3.9% [95% CI, -6.8% to 1.4%]; relative risk, 0.61 [95% CI, 0.33 to 1.13], P = .12).

21 may decrease use of noninvasive ventilation (relative risk, 0.64; 95% CI, 0.34-1.22; moderate certain

22 , -3.8 incident cases per 1000 person-years; relative risk, 0.68 [95% CI, 0.54-0.87]), midterm DAPT (

23 , -3.7 incident cases per 1000 person-years; relative risk, 0.69 [0.51-0.95]).

24 d in the 5-mg group than in the 20-mg group (relative risk, 0.71; 97.5% CI, 0.59 to 0.86).

25 pacemaker implantation after the procedure (relative risk, 0.72; corrected P<0.0001).

26 of AF recurrence compared with DAT >1 year (relative risk, 0.73 [95% CI, 0.65-0.82]; P<0.001).

27 l infection was 4.8% and 6.3%, respectively (relative risk, 0.76; 95% CI, 0.56 to 1.03).

28 Q P=0.55) with a similar estimate of effect (relative risk, 0.78 [95% CI, 0.71-0.85]; P<0.001).

29 lower risk of cardiovascular events (pooled relative risk, 0.80 [95% CI, 0.73-0.87]; 9 RCTs [n = 12

30 ong metronidazole-exposed children (adjusted relative risk, 0.81 [95% CI, 0.41 to 1.59]).

31 in the 10-mg group than in the 20-mg group (relative risk, 0.81; 97.5% CI, 0.67 to 0.96) and in the

32 nty), or postextubation respiratory failure (relative risk, 0.82; 95% CI, 0.48-1.41; very low certain

33 8; corrected P=0.005), cardiovascular death (relative risk, 0.82; corrected P=0.002), and rehospitali

34 hort than in the comparison cohort (adjusted relative risk, 0.84, 95% confidence interval, 0.78 to 0.

35 f 1406 infants (23.5%) in the placebo group (relative risk, 0.84; 95% confidence interval [CI], 0.72

36 2), and rehospitalization for heart failure (relative risk, 0.84; corrected P<0.0001).

37 moderate certainty), serious complications (relative risk, 0.87; 95% CI, 0.71-1.06), apneic time (me

38 9 fetuses and infants (29.2%), respectively (relative risk, 0.88; 95% CI, 0.78 to 0.99; P = 0.04); th

39 a lower yearly incidence of all-cause death (relative risk, 0.88; corrected P=0.005), cardiovascular

40 cebo versus 19 of 59 allocated to ramelteon (relative risk, 0.8; 95% CI, 0.5-1.4; p = 0.516).

41 itor based vs nonnucleoside inhibitor based: relative risk, 0.90; P = .186) were not associated with

42 difference, -5.0% [95% CI, -11.6% to 2.6%]; relative risk, 0.91 [95% CI, 0.80 to 1.04], P = .18).

43 certainty), but had no effect on mortality (relative risk, 0.93; 95% CI, 0.57-1.52; moderate certain

44 95% CI, -6.75 to 1.05; P = .15) (unadjusted relative risk, 0.93; 95% CI, 0.85-1.03).

45 , -2.78% [95% CI, -7.80% to 2.25%]; adjusted relative risk, 0.94 [95% CI, 0.84-1.05]).

46 d with an increased risk of hospitalization (relative risk, 0.96; 95% CI, 0.77-1.19) after adjusting

47 han metronidazole-treated patients (adjusted relative risk, 0.96; 95% confidence interval [CI], .77 t

48 ccurrence rate of peri-intubation hypoxemia (relative risk, 0.98; 95% CI, 0.68-1.42; 0.3% absolute ri

49 mong similar-aged non-cancer trial subjects (relative risk: 0.38; p < 0.01), translating into a risk

50 as 14% with netarsudil and 21% with placebo (relative risk: 0.6; 95% confidence interval: 0.3-1.3; P

51 ar (560/1,895 [29.6%] vs. 539/1,920 [28.1%]; relative risk 1.05 [95% confidence interval, 0.95-1.16])

52 risk difference 2.68%, 95% CI -0.96 to 6.33; relative risk 1.09, 95% CI 0.97 to 1.23, p=0.114).

53 nd 96 (37%) of 259 in the intravenous group (relative risk 1.11, 95% CI 0.89-1.37).

54 ) group and two events in the placebo group; relative risk 1.25, 95% CI 0.43-3.66; Fisher's exact p=1

55 ile increasing the rate of RSV B infections (relative risk 1.36 [95% CI, .73-2.56] in the 1-dose grou

56 among patients who received JAK inhibitors (relative risk 1.57; 95% confidence interval 1.04-2.37).

57 bolic syndrome than those with classes I/II [relative risk 1.99 (95% CI 1.19, 3.34)].

58 ween milk volume and fracture risk (adjusted relative risk = 1.04, 95% confidence interval: 0.87, 1.2

59 milk-fat content and fracture risk (adjusted relative risk = 1.05, 95% confidence interval: 0.84, 1.3

60 al mental illness (18.1% vs. 16.0%; adjusted relative risk = 1.11, 95% confidence interval: 1.07, 1.1

61 itself was harmful to survival across sexes (relative risk = 1.161, 95% CI: 1.027, 1.345; P = 0.026).

62 , -0.04% [95% CI, -4.80% to 4.71%]; adjusted relative risk, 1.00 [95% CI, 0.86-1.16]) or in any of th

63 ge (97 children [26%] vs. 94 children [26%]; relative risk, 1.03; 95% confidence interval, 0.81 to 1.

64 (difference, 3.3% [95% CI, -3.3% to 10.0%]; relative risk, 1.10 [95% CI, 0.91-1.34]; P = .33).

65 5% CI, 0.86-1.57; low certainty), mortality (relative risk, 1.12; 95% CI, 0.82-1.53; moderate certain

66 nasal cannula had no effect on reintubation (relative risk, 1.16; 95% CI, 0.86-1.57; low certainty),

67 591 (24.4%) in the face-mask group (adjusted relative risk, 1.16; 95% confidence interval [CI], 0.90

68 .30-5.30), and respiratory failure (adjusted relative risk, 1.19; 95% CI, 1.03-1.43).

69 4% of those in the face-mask group (adjusted relative risk, 1.21; 95% CI, 0.90 to 1.63), and admissio

70 ed with 43.7% of those in the control group (relative risk, 1.22; 95% CI, 1.10 to 1.35).

71 d in 11.2% and 10.1%, respectively (adjusted relative risk, 1.27; 95% CI, 0.84 to 1.93).

72 and in hospital mortality (5.6% versus 4.2%; relative risk, 1.34 [95% CI, 1.07-1.66]; P=0.01).

73 e difference, 11.5% [95% CI, 2.3% to 23.2%]; relative risk, 1.36 [95% CI, 1.07 to 1.73], P = .01).

74 hospitalization in a similar adjusted model (relative risk, 1.39; 95% CI, 0.90-2.15).

75 edules (97.1 vs. 79.0 per 1000 patient-days; relative risk, 1.53; 95% confidence interval [CI], 1.37

76 .01-1.03; p = 0.017), and use of paralytics (relative risk, 1.54; 1.26-1.90, p < 0.001).

77 ules (181.3 vs. 131.5 per 1000 patient-days; relative risk, 1.56; 95% CI, 1.43 to 1.71).

78 cute respiratory distress syndrome (adjusted relative risk, 1.5; 1.1-2.1).

79 er 1 year (45.2%) than the UC group (27.6%) (relative risk, 1.6 [CI, 1.1 to 2.4]).

80 mortality in patients with sepsis (adjusted relative risk, 1.66; 95% CI, 1.39-1.98), acute kidney in

81 SE-THV (19.8%) compared with BE-THV (11.9%; relative risk, 1.68 [95% CI, 1.46-1.91]; P<0.0001).

82 y (difference, 1.8% [95% CI, -0.7% to 4.3%]; relative risk, 1.76 [95% CI, 0.79-3.94]; P = .17).

83 ravalvular regurgitation (15.5% versus 8.3%; relative risk, 1.90 [95% CI, 1.63-2.22]; P<0.0001) and i

84 9, p < 0.0001) and recurrence-free survival (Relative Risk: 1.299, p < 0.0001) in patients with HCC.

85 sses versus women without diabetes (adjusted relative risks: 1.09-1.12), but results for class 2 were

86 6.3% in patients without COVID-19, p=0.0197; relative risk=1.6).

87 te with SRI was 17% compared to 7% with IUI (relative risk 2.33; p = 0.032) across both cycles.

88 Children <5 years old had the highest relative risk (2.07).

89 associated with grade IV venom anaphylaxis (relative risk = 2.0; P < .05) and more prevalent in both

90 schemic attacks (14/19 vs 6/18 with vehicle, relative risk = 2.21, p < 0.022), and doubled infarct vo

91 apital after the disaster elevated the risk (relative risk = 2.44, 95% confidence interval: 1.33, 4.4

92 95th percentile threshold (7.9% versus 3.9%; relative risk, 2.01 [CI, 1.70-2.38]).

93 observed for fathers with siblings with ASD (relative risk, 2.08; 95% confidence interval, 1.53-2.67)

94 ents with both acute kidney injury (adjusted relative risk, 2.38; 95% CI, 1.75-2.98) and surgery (adj

95 I, 1.39-1.98), acute kidney injury (adjusted relative risk, 2.63; 95% CI, 1.30-5.30), and respiratory

96 ent prognostic factors for overall survival (Relative Risk: 2.129, p < 0.0001) and recurrence-free su

97 onegatives 64% vs. 26% (p = 0.004); adjusted relative risk: 2.20 (95% confidence intervals 1.00-4.80;

98 positively associated with high IOP at POD1 (relative risk = 3.23, 95% confidence interval 0.96-10.84

99 er rates of ASD than the general population (relative risk, 3.05; 95% confidence interval, 2.52-3.64)

100 cute respiratory distress syndrome (adjusted relative risk, 3.7; 95% CI, 2.0-6.9).

101 Suptavumab prevented RSV A infections (relative risks, .38; 95% confidence interval [CI], .14-1

102 38; 95% CI, 1.75-2.98) and surgery (adjusted relative risk, 6.17; 95% CI, 4.81-7.97).

103 ared with 11% of patients from the MT group (relative risk, 6.52 [95% CI, 2.50 to 17.03]; P < 0.001).

104 832) compared with control subjects (6/7509; relative risk=6; P=0.00067).

105 ssociated with worse final BCVA (P = 0.0101; relative risk, 7; 95% confidence interval, 1.01-44.63).

106 ith increased risk for systemic anaphylaxis (relative risk = 9.5; P = .007).

107 Dichotomous data are presented as relative risk (95% CIs) and p value, and continuous data

108 The relative risks (95%CI) of all-cause mortality in males v

109 Ultimately, the relative risk a predator poses to a species and the prob

110 The maximum relative risk achievable for subjects at the 99th risk p

111 nfants (49.8%) in the lower-threshold group (relative risk adjusted for birth-weight stratum and cent

112 isk factors in most age-groups, with highest relative risks among 20-39 year-olds (respective aRRs 1.

113 ated age-dependent effects, with the highest relative risks among adults aged 20-39.

114 h the best posttransplant outcomes (marginal relative risk and 95% confidence interval, 1.161.501.95)

115 Age-adjusted relative risks and tumor subtype specific risks were est

116 rted as number of cases (%), median (range), relative risk, and analyzed using Mann Whitney U test, C

117 food insecure hotspot communities [adjusted relative risk (aRR) = 1.13, 95% CI:1.01-1.27] using a ge

118 Adjusted relative risks (aRRs) and absolute risk differences (ARD

119 top 30 trajectories with the highest average relative risks comprised microvascular, macrovascular, a

120 Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression m

121 Lifetime Attributable Risk (LAR) and Excess Relative Risk (ERR) of cancer mortality.

122 CA-AKI was associated with an increased relative risk for 90-day death, need for dialysis, or pe

123 An FH of HPC conveyed the greatest relative risk for all PC subtypes combined (RR, 2.30; 95

124 This study sought to characterize the relative risk for and incidence of serious adverse outco

125 The relative risk for CDI with asymptomatic carriage of a to

126 The relative risk for cleavage was 2.36 times lower in the e

127 confidence interval), and the odds ratio and relative risk for each risk factor were calculated.

128 CI, 1.51-3.07), at any time point, adjusted relative risk for fluid overload was 2.79 (95% CI, 1.55-

129 ortality: after 3 days of ICU stay, adjusted relative risk for fluid overload was 8.83 (95% CI, 4.03-

130 .30- to 2.36-fold (p values < .02) increased relative risk for higher number of areas of child neurod

131 higher census tract poverty level (P < .001; relative risk for highest [>=20%] vs lowest [<5%] census

132 injury (CA-AKI) associates with an increased relative risk for serious adverse outcomes.

133 The relative risk for shrinkage/fusion of blastomeres with s

134 he PAR4 Leu310 allele had a 15% reduction in relative risk for VTE (odds ratio, 0.85; 95% confidence

135 ) placebo versus 1/121 (0.8%) Abx, P = 0.01 [relative risk for WI 7.9 (95% confidence interval: 1.0-6

136 The adjusted relative risk for women versus men of developing the out

137 om 1.3 to 14.3 for total SMM and even higher relative risks for nontransfusion SMM (to 32.4).

138 ffering mortality impacts based on different relative risks for the disease.

139 rst genomically-confirmed assessments of CDI relative risk from asymptomatic carriage of toxin-encodi

140 ocused on associations with large magnitude (relative risks >= 2.0).

141 usting for other risk factors (multivariable relative risk, highest vs lowest quartile, 1.43; 95% con

142 The relative risk in patients with recurrences to develop lu

143 ed to treat (NNT(5)) calculations, and a 42% relative risk increase in major bleeding events was used

144 iseases exhibit an approximately ten percent relative risk increase.

145 osures with statistically significant, large relative risks indicating that cases were less frequentl

146 nce of peri-implant disease and generate new relative risk indicators.

147 , and Eastern regions, exhibited significant relative-risk levels.

148 These diseases' decreasing relative risks might be driven by the documented boostin

149 003 and 13 (7%) placebo participants, with a relative risk of 0.35 (0.19-0.65).

150 We estimated the relative risk of 30-day readmission and 30-day mortality

151 ter DAT <=1 year was associated with a lower relative risk of AF recurrence compared with DAT >1 year

152 By statistically modeling the relative risk of an adverse outcome for thousands of sub

153 dicated that Drymarchon couperi had a higher relative risk of apparent ophidiomycosis (lesions presen

154 we performed bivariate analysis to determine relative risk of baseline or acquired resistance to othe

155 change in antibiotic prophylaxis guidelines (relative risk of change 1.06 [95% CI, 0.94-1.20]).

156 ding 10 years were associated with a reduced relative risk of CRC in men and women.

157 patients with AR exhibited excess mortality (relative risk of death >1), which rose steeply in invers

158 as independently associated with a decreased relative risk of death (RRfor each additional day = 0.55

159 nued day of bacteremia was associated with a relative risk of death of 1.16 (95% confidence interval,

160 ociated with the highest 5-year absolute and relative risk of death, and decrease in lifespan within

161 ric surgery is known to reduce the long-term relative risk of death, but its effect on life expectanc

162 iage of vaccine-serotype pneumococci via the relative risk of detecting these serotypes among vaccina

163 P presentations, support a twofold increased relative risk of diabetes compared with the general popu

164 t will allow decision-makers to evaluate the relative risk of different shipping routes.

165 that there was a significant increase in the relative risk of incident gastric cancer across the quin

166 A similar increase in the relative risk of incident gastric cancer was observed ac

167 n phase based on estimated reductions in the relative risk of infection.

168 who were safety-net reliant had a 30% higher relative risk of initiating dialysis at nonprofit/indepe

169 that, within a few years, statins lower the relative risk of major atherosclerotic events by about 2

170 Relative risk of mortality or poor neurological function

171 There was a 29% decrease in the relative risk of new caries experience in the DR-BNI gro

172 nomial regression model was used to estimate relative risk of outcomes in subgroups by screening tech

173 essing its association with the neighborhood relative risk of prevalent type 2 diabetes mellitus.

174 For DBT+SM, adjusted relative risk of recall (VDG 2: 1.8; P < .001; VDG 3: 2.

175 Adjusted relative risk of recall and screen-detected breast cance

176 whereas no differences were observed for DM (relative risk of recall for VDG 2: 1.3; P = .06; VDG 3:

177 DG 3: 1.1; P = .41; VDG 4: 1.1; P = .71; and relative risk of screen-detected breast cancer for VDG 2

178 ereas CA-AKI is associated with an increased relative risk of serious, adverse 90-day outcomes, the i

179 lavage (BAL) samples, it did not reduce the relative risk of SIV-induced TB reactivation in ART-trea

180 gher Index scores were associated with lower relative risk of suboptimal retention (N=2,576; LR aRR 0

181 e weighted score were associated with higher relative risk of T2D after 1 y of follow-up.

182 iated with a 30% (95% CI: 1.12, 1.51) higher relative risk of T2D for each 1-SD increment.

183 the healthiest lifestyle and low T2D-GR, the relative risk of T2D for participants with the healthies

184 The relative risk of TB in prisons compared to community was

185 The statistical analysis estimates the relative risk of the Ebola endpoint occurring from after

186 atform, we asked 15 clinicians to assess the relative risk of the subpopulation defined by each rule

187 h included controlled studies, to assess the relative risk of these events.

188 completely to e-cigarettes may reduce their relative risk of tobacco-related disease.

189 alculated mVE as 1 minus the Mantel-Haenszel relative risk of vaccine on incident cases, and determin

190 o 44 kg/m(2) and greater than 45 kg/m(2) had relative risks of 2.68 (95% CI, 1.43 to 5.04) and 4.18 (

191 n physical activity prevalence (2001-16) and relative risks of all-cause mortality for 168 countries.

192 Univariable analyses regarding the relative risks of complications occurring after status e

193 lower non-recurrent, health-related SMRs and relative risks of developing grade 3-5 chronic health co

194 % CI, 1.24 to 1.36); they had slightly lower relative risks of initiating dialysis at for-profit and

195 Absolute and relative risks of meeting or exceeding 60 dBA differ con

196 ort-specific survival data, we estimated the relative risks of mortality from ages 95 to 103 years as

197 , and 35 or 36 weeks), we estimated adjusted relative risks of neonatal death and absolute rate diffe

198 wer Apgar scores were associated with higher relative risks of neonatal death and greater absolute ra

199 ence interval [CI], 0.09 to 0.59; P = 0.002; relative risk [post hoc analysis], 0.37; 95% CI, 0.16 to

200 ntified medical comorbid conditions had high relative risks ranging from 1.3 to 14.3 for total SMM an

201 The relative risk ratio (difference-in-differences) was 0.99

202 e likely to undergo primary laser barricade (relative risk ratio [RRR] 1.68, P < .001), primary SB (R

203 [CI], 1.65-6.84) and multiclade communities (relative risk ratio [RRR], 9.51; 95% CI, 4.36-20.73) wer

204 nt stunting from 12 through 24 months with a relative risk ratio of 1.51 (95% CI 1.21, 1.88).

205 patients undergoing orthopedic surgery, the relative risk ratio was 0.84 (95% CI 0.75-0.95).

206 The relative risk ratio was 2.4 (95% CI: 1.6, 3.4; P < .001)

207 offspring's asthma without nasal allergies (relative risk ratio, 2.31 [95% CI, 1.23-4.33]).

208 Relative risk ratios were computed to test the associati

209 tors but without high genetic risk and a 31% relative risk reduction (HR, 0.69 [0.55-0.86], P=0.0012)

210 In contrast, there was a 13% relative risk reduction (HR, 0.87 [0.75-0.998], P=0.047)

211 , 95% confidence interval (CI) = 19.1-52.4%; relative risk reduction (RRR) = 67.8%] and success rate

212 Antiplatelet drugs induce only a moderate relative risk reduction after atherothrombosis, and thei

213 meta-analysis data on cardiovascular disease relative risk reduction and bleeding risk.

214 ifies the affected sibling, and also compute Relative Risk Reduction as a function of risk score thre

215 groups of 6.0% and 1.5%, respectively, and a relative risk reduction by alirocumab of 37% in the high

216 A 12% relative risk reduction in cardiovascular disease events

217 There was a gradient in relative risk reduction in primary events with sacubitri

218 RIER and ODYSSEY OUTCOMES demonstrated a 31% relative risk reduction in VTE with PCSK9 inhibition (HR

219 A consistent and similar relative risk reduction was seen for benefit of rivaroxa

220 coronary syndrome and a larger absolute and relative risk reduction with alirocumab treatment, provi

221 confidence interval: 0.80 to 1.24; trend in relative risk reduction: p(interaction) = 0.15).

222 The relative risk reductions with dapagliflozin for CV death

223 mined by sex, age, and statin-associated T2D relative risk (RR) (range: 1.11-1.55).

224 who had NPWT compared to standard dressings; relative risk (RR) 0.56 (95% confidence interval 0.30-1.

225 s complications following abdominal surgery [relative risk (RR) 0.56; 95% confidence interval (CI) 0.

226 d that iNPWT reduced SSI [28 RCTs, n = 4398, relative risk (RR) 0.61, 95% confidence interval [CI]: 0

227 fects on mortality: unrevascularized post-MI relative risk (RR) 0.68 (95% CI, 0.45-1.03); P=0.07; mul

228 the risk factors for mortality were male sex Relative Risk (RR) 2.88 (p = 0.03), hypoglycemia (RR) 5.

229 en cadmium and presence of lacunar infarcts [relative risk (RR) = 1.024 (95% CI: 1.004, 1.045) per 10

230 th preterm delivery in both early childhood (relative risk (RR) = 1.12, 95% confidence interval (CI):

231 fe episodic memory and associative learning (relative risk (RR) = 1.38, 95% confidence interval (CI):

232 30) was lower than Group I (9/134, corrected relative risk (RR) = 18.44, 95% CI: 1.08-313.56) and Gro

233 r and had higher risk of detectable cadmium, relative risk (RR) = 2.2 (95% CI: 1.3, 3.7), RR = 1.4 (9

234 dies were included if they reported adjusted relative risk (RR) estimates and 95% confidence interval

235 ite, and generalised linear models to obtain relative risk (RR) estimates and associated confidence i

236 -effects model to calculate disease-specific relative risk (RR) meta-estimates.

237 The prespecified noninferiority margin was a relative risk (RR) of 0.90.

238 re revealed that donor aged 3-10 years had a relative risk (RR) of 3.94 (2.86-5.44), and donor aged >

239 Relative risk (RR) of ASD was estimated using log-binomi

240 ividual insecticide-treated net (ITN) use on relative risk (RR) of confirmed malaria.

241 ients in hospitals that introduced CCRT, the relative risk (RR) of FTR was 0.84, (95% confidence inte

242 t for non-inferiority was done to test for a relative risk (RR) of more than 0.95.

243 Meta-analysis showed an adjusted relative risk (RR) of mortality at 1 year of 0.99 (95% C

244 Relative risks (RR) of developing MCI when exposed to sl

245 as insulin cessation at 1-year post-surgery: relative risks (RR) summarising predictive factors were

246 the relative efficacy of interventions using relative risks (RR).

247 Individuals aged 5-9 years (relative risk [RR] 0.32 [95% CI 0.11-0.63]) and those ol

248 ome (0.4% [10/2,281] versus 1.0% [23/2,280]; relative risk [RR] 0.43 [95% confidence interval [CI] 0.

249 in the dihydroartemisinin-piperaquine group (relative risk [RR] 0.64, 95% CI 0.39 to 1.04).

250 non-SOT patients (40% and 43%, respectively; relative risk [RR] 0.92; 95% confidence interval [CI]: 0

251 PrEP implementation was associated with 25% (relative risk [RR] 1.254, 95% confidence interval [CI] 1

252 , CQI significantly increased VL monitoring (relative risk [RR] 1.38, 95% CI 1.21 to 1.57, p < 0.001)

253 r than in the SOC arm (34%, 18/53; P < .001; relative risk [RR] 2.48, 95% CI 1.54-3.95), and the prop

254 , T2D/IGT risk was lower per year later AAM (relative risk [RR] = 0.91, 95% CI 0.89-0.93, p < 0.001,

255 reased risk of cognitive decline at 3 years (relative risk [RR] = 3.49, 95% confidence interval [CI]

256 ly associated with an increased risk of CHD (relative risk [RR] in the top tertile: 1.58 [95% confide

257 nists), these agents showed improved safety (relative risk [RR] of major bleeding, 0.61; 95% confiden

258 was stronger for intracerebral haemorrhage (relative risk [RR] per 280 g per week 1.58, 95% CI 1.36-

259 F risk in both cohorts: CER (ceramide) 16:0 (relative risk [RR] per SD in PREDIMED, 1.28 [95% CI, 1.1

260 factors including malignancy (7.0% vs 29.4%; relative risk [RR], 0.2 [95% confidence interval {CI}, .

261 low-up (13 trials, n = 21 700; 7.4% vs 9.2%; relative risk [RR], 0.82 [95% CI, 0.73-0.92]).

262 ers in the BD and C-BD groups, respectively; relative risk [RR], 0.87; P = .46).

263 educed the risk of a positive baseline IGRA (relative risk [RR], 0.89 [95% confidence interval {CI} .

264 Being young at the time of cancer treatment (relative risk [RR], 0.91 [95% CI, 0.88 to 0.95] by year

265 V control was less likely in older patients (relative risk [RR], 0.97 per year; 95% CI, 0.96 to 0.98

266 not associated with a reduced risk of death (relative risk [RR], 0.99 [95% CI, 0.90-1.09]).

267 Increasing age (relative risk [RR], 1.02; 95% confidence interval [CI]:

268 p (54.8%) than in the control group (40.4%) (relative risk [RR], 1.30; 95% confidence interval [CI],

269 of drug use abstinence (15 trials, n = 3636; relative risk [RR], 1.60 [95% CI, 1.24 to 2.13]; absolut

270 sociated with the presence of any 9v HR-HPV (relative risk [RR], 1.8 [95% confidence interval {CI}, 1

271 with intrahepatic cholestasis of pregnancy (relative risk [RR], 10.64; 95% confidence interval [CI],

272 with higher risk of antibiotic prescribing (relative risk [RR], 2.3; 95% confidence interval [CI], 1

273 was associated with a 20% lower risk of T2D (relative risk [RR]: 0.80; 95% CI 0.77, 0.84; p < 0.001),

274 s, 56%) was associated with lymphadenopathy (relative risk [RR]: 1.7; 95% confidence interval [CI]: 1

275 tatus, and medication use, specifically, the relative risks (RRs) and 95% confidence interval (95% CI

276 effects models were used to estimate summary relative risks (RRs) and 95% confidence intervals (CIs)

277 We estimated relative risks (RRs) and 95% confidence intervals (CIs)

278 Relative risks (RRs) associated with each subtype, adjus

279 Poisson regression models were fit to obtain relative risks (RRs) for associations between in utero a

280 April 11, 2018, and June 10, 2020, to obtain relative risks (RRs) or population attributable fraction

281 Relative risks (RRs) per cohort-specific range between m

282 Summary relative risks (RRs) were calculated in a random effects

283 The prevalence and adjusted relative risks (RRs) were evaluated, and the liability t

284 Relative risks (RRs) were pooled using random-effects me

285 intervals (CIs) for continuous outcomes and relative risks (RRs) with corresponding 95% CIs for dich

286 Pooled relative risks (RRs), standard mean differences of 95% c

287 ex segregation analysis was used to estimate relative risks (RRs; relative to country-specific popula

288 related deaths, assuming relative impact (as relative risks [RRs]) of the COVID-19 pandemic (compared

289 ere positively associated with incident T2D (relative risks [RRs]: 1.14-1.21; all P < 0.001), after m

290 Relative risk scores on a scale of 100 represent the int

291 Event Reporting System, are used to compute relative risk scores.

292 meta-analyses were used to estimate summary relative risks (SRRs) and 95% confidence intervals (CIs)

293 the first time a collection of diseases with relative risks that appear to decrease immediately after

294 5.3%) of 623 males had myopia making females relative risk to be 1.5 times that of males.

295 emographic and Health Surveys with published relative risks to estimate the potential distribution of

296 imately 55.2% (95% CI: 25.7, 68.5) of excess relative risk was due to neither interaction nor mediati

297 Standardized relative risks were calculated bidirectionally for any S

298 were evaluated by Kaplan-Meier analysis, and relative risks were estimated using proportional hazards

299 The highest bidirectional relative risks were for invasive and in situ skin cancer

300 p between choice of NOAC and major bleeding, relative risk with rivaroxaban was 1.89 (95% CI, 1.06-2.